References
[1] Global Cancer Observatory (http://gco.iarc.fr/) International
Agency Research on Cancer 2022
[2] SEER 17 2012–2018, All Races, Both Sexes by SEER Combined
Summary Stage. https://seer.cancer.gov/statfacts/html/pancreas.html
[3] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®
)Pancreatic Adenocarcinoma Version 1.2022-February
24,2022.https://www.nccn.org/professionals/
physician_gls/pdf/pancreatic.
[4] Webber C, Gospodarowicz M, Sobin LH, Wittekind C, et al.
Improving the TNM classification: findings from a 10-year continuous
literature review. Int J Cancer. 2014 Jul 15;135(2):371-8. doi:
10.1002/ijc.28683. PMID: 24921087.
[5] van Roessel S, Kasumova GG, Verheij J, et al. International
Validation of the Eighth Edition of the American Joint Committee on
Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic
Cancer. JAMA Surg. 2018 Dec 1;153(12):e183617. doi:
10.1001/jamasurg.2018.3617. Epub 2018 Dec 19. Erratum in: JAMA Surg.
2019 Feb 20;: PMID: 30285076; PMCID: PMC6583013.
[6] Shin DW, Lee JC, Kim J, et al. Validation of the American Joint
Committee on Cancer 8th edition staging system for the pancreatic ductal
adenocarcinoma. Eur J Surg Oncol. 2019 Nov;45(11):2159-2165. doi:
10.1016/j.ejso.2019.06.002. Epub 2019 Jun 3. PMID: 31202572.
[7] Kwon W, He J, Higuchi R, et al. Multinational validation of the
American Joint Committee on Cancer 8th edition pancreatic cancer staging
system in a pancreas head cancer cohort. J Hepatobiliary Pancreat Sci.
2018 Sep;25(9):418-427. doi: 10.1002/jhbp.577. PMID: 30118171.
[8] Abdel-Rahman O. Evaluation of the 8th AJCC staging system for
pathologically versus clinically staged pancreatic adenocarcinoma: A
time to revisit a dogma? Hepatobiliary Pancreat Dis Int. 2018
Feb;17(1):64-69. doi: 10.1016/j.hbpd.2018.01.014. Epub 2018 Jan 31.
PMID: 29428107.
[9] Schouten TJ, Daamen LA, Dorland G, et al; Dutch Pancreatic
Cancer Group. Nationwide Validation of the 8th American Joint Committee
on Cancer TNM Staging System and Five Proposed Modifications for
Resected Pancreatic Cancer. Ann Surg Oncol. 2022 Sep;29(9):5988-5999.
doi: 10.1245/s10434-022-11664-4. Epub 2022 Apr 25. Erratum in: Ann Surg
Oncol. 2022 Jul 7;: PMID: 35469113; PMCID: PMC9356941.
[10] Oba A, Croce C, Hosokawa P, et al. Prognosis Based Definition
of Resectability in Pancreatic Cancer: A Road Map to New Guidelines. Ann
Surg. 2022 Jan 1;275(1):175-181. doi: 10.1097/SLA.0000000000003859.
PMID: 32149822.
[11] Chen YT, Huang ZP, Zhou ZW, et al. Equipping the American Joint
Committee on Cancer staging for resectable pancreatic ductal
adenocarcinoma with tumor grade: a recursive partitioning analysis. Med
Oncol. 2016 Nov;33(11):122. doi: 10.1007/s12032-016-0839-4. Epub 2016
Oct 11. PMID: 27730526; PMCID: PMC5059399.
[12] Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy:
Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol.
2021 Feb 1;11:629722. doi: 10.3389/fimmu.2020.629722. PMID: 33597954;
PMCID: PMC7882695.
[13] Kinny-Köster B, Habib JR, Wolfgang CL, et al. Favorable tumor
biology in locally advanced pancreatic cancer-beyond CA19-9. J
Gastrointest Oncol. 2021 Oct;12(5):2484-2494. doi: 10.21037/jgo-20-426.
PMID: 34790409; PMCID: PMC8576224.
[14] Dall’Olio FG, Marabelle A, Caramella C, et al. Tumour burden
and efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2022
Feb;19(2):75-90. doi: 10.1038/s41571-021-00564-3. Epub 2021 Oct 12.
PMID: 34642484.
[15] König AK, Gros H, Hinz U, et al. Refined prognostic staging for
resected pancreatic cancer by modified stage grouping and addition of
tumour grade. Eur J Surg Oncol. 2022 Jan;48(1):113-120. doi:
10.1016/j.ejso.2021.07.020. Epub 2021 Jul 26. PMID: 34344573.
[16] Macías N, Sayagués JM, Esteban C, et al. Histologic Tumor Grade
and Preoperative Bilary Drainage are the Unique Independent Prognostic
Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After
Pancreaticoduodenectomy. J Clin Gastroenterol. 2018 Feb;52(2):e11-e17.
doi: 10.1097/MCG.0000000000000793. PMID: 28059940.
[17] Kang YM, Wang H, Li R, et al. Prognostic Role of Carbohydrate
Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic
Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2021
Jan-Dec;20:15330338211043030. doi: 10.1177/15330338211043030. PMID:
34617852; PMCID: PMC8642114.
[18] Berger AC, Meszoely IM, Ross EA, et al.Undetectable
preoperative levels of serum CA 19-9 correlate with improved survival
for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol.
2004;11:644–9.
[19] Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative
CA19-9 levels can predict stage and survival in patients with resectable
pancreatic adenocarcinoma. J Clin Oncol. 2006;24:2897–902.
[20] Waraya M, Yamashita K, Katagiri H, et al. Preoperative serum
CA19-9 and dissected peripancreatic tissue margin as determiners of
long-term survival in pancreatic cancer. Ann Surg
Oncol.2009;16:1231–40.
[21] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
® )Pancreatic Adenocarcinoma Version 1.2022-February 24, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.
[22] Murai J, Soga S, Saito H, et al.(2013) Study on the mechanism
causing elevation of serum CA19-9 levels in diabetic patients. Endocr J
60:885–891.
[23] Roback, J., et al. AABB Technical Manual. 16th edition..
American Association of Blood Banks;2008.
[24] Tempero MA, et al. Relationship of carbohydrate antigen 19-9
and Lewis antigens in pancreatic cancer. Cancer Res. 1987;
47(20):5501–3. [PubMed: 3308077]
[25] Uchida E, et al. Correlative studies on antigenicity of
pancreatic cancer and blood group types.Cancer Detect Prev Suppl.
1987:145–8. [PubMed: 3319143]
[26] Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a
serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann
Intern Med. 1989 May 1;110(9):704-9. doi: 10.7326/0003-4819-110-9-704.
PMID: 2930108.
[27] Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA,
CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007.
PMID: 15698733.
[28] Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially
resectable pancreatic cancer: perspective to adjust surgical and
perioperative therapy. Ann Surg Oncol. 2013 Jul;20(7):2188-96. doi:
10.1245/s10434-012-2809-1. Epub 2012 Dec 18. PMID: 23247983.
[29] Kumar V, Fausto N, Abbas A. Robbins and Cotran pathologic basis
of disease. 7th ed. Philadelphia: Saunders; 2004.
[30] Telloni SM. Tumor Staging and Grading: A Primer. Methods Mol
Biol. 2017;1606:1-17. doi: 10.1007/978-1-4939-6990-6_1. PMID: 28501990.
[31] Macías N, Sayagués JM, Esteban C, et al. Histologic Tumor Grade
and Preoperative Bilary Drainage are the Unique Independent Prognostic
Factors of Survival in Pancreatic Ductal Adenocarcinoma Patients After
Pancreaticoduodenectomy. J Clin Gastroenterol. 2018 Feb;52(2):e11-e17.
doi: 10.1097/MCG.0000000000000793. PMID: 28059940.
[32] König AK, Gros H, Hinz U, et al. Refined prognostic staging for
resected pancreatic cancer by modified stage grouping and addition of
tumour grade. Eur J Surg Oncol. 2022 Jan;48(1):113-120. doi:
10.1016/j.ejso.2021.07.020. Epub 2021 Jul 26. PMID: 34344573.